COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 10 of 80 for:    CARBAMAZEPINE AND Psychotropic

Carbamazepine Extended-Release for the Treatment of Bipolar Depression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00203567
Recruitment Status : Completed
First Posted : September 20, 2005
Last Update Posted : June 24, 2008
Information provided by:
Tuscaloosa Research & Education Advancement Corporation

Brief Summary:
To study the efficacy and safety of beaded extended-release Carbamazepine (Equetro) in the treatment of patients with Bipolar Disorder with a Major Depressive Episode.

Condition or disease Intervention/treatment Phase
Bipolar Depression Drug: carbamazepine ER Phase 4

Detailed Description:
Patients with Bipolar I or II Disorder with a Major Depressive Episode who sign informed consent and meet eligibility criteria will begin treatment with extended release carbamazepine (ERC-CBZ ). The dose of ERC-CBZ will be initiated at 200mg twice daily and increased as tolerated by 200mg/day every 3 days up to 1200mg/day by week 2 (target dose). Then the dose may be increased at the investigator's discretion, up to1600mg/day as tolerated by week 8, if needed for a greater therapeutic response. Efficacy will be assessed biweekly with the Montgomery-Asberg Depression Rating Scale (MADRS) and Clinical Global Impression-Bipolar (CGI-BP). Safety is assessed biweekly with adverse events self-reports and laboratory evaluations. ).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Carbamazepine Extended-Release for the Treatment of Bipolar Depression
Study Start Date : August 2005
Actual Primary Completion Date : February 2007
Actual Study Completion Date : May 2008

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Equetro
Drug: carbamazepine ER
Active study drug, no comparator

Primary Outcome Measures :
  1. To study the efficacy and safety of beaded extended-release Carbamazepine (Equetro) in the treatment of patients with Bipolar Disorder with a Major Depressive Episode. [ Time Frame: 8 weeks ]

Secondary Outcome Measures :
  1. The treatment phase will include Mean Change from Baseline to Endpoint (Week 8 LOCF) on the CGI-BP, Q-LES-Q, and Ham-A. [ Time Frame: 8 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 19 -65.
  • Diagnosis of Bipolar I or II Disorder, currently experiencing a major depressive episode without psychotic features, as confirmed by the Mini International Neuropsychiatric Interview (M.I.N.I.).
  • Must have experienced at least two previous mood episodes during the past 10 years, at least one of which was a hypomanic, full manic or mixed episode. The current depressive episode must be ≥ 2 weeks, but ≤ 2 years in duration.
  • Must currently have clinically significant depressive symptoms as defined by a CGI-S total score of ≥ 4.
  • Must have been washed out of all psychotropic medications (except for the allowed concomitant sedatives for insomnia) for their bipolar illness for at least 3 days for mood stabilizers and 1 week for antidepressants prior to study drug initiation (medications should be tapered at the investigator's discretion prior to washout), while continuing to meet entry criteria for depressive symptoms. Must be willing to discontinue all psychotropic medication (except for the allowed concomitant sedative for insomnia) during the study period.
  • No substance abuse/dependence for the previous 4 weeks (except for nicotine/caffeine)
  • Must give informed consent, and/or consent must be obtained from a legally acceptable representative (as required by IRB) prior to the initiation of any protocol required procedures.
  • Must be able to understand the nature of the study, agree to comply with the prescribed dosage regiments, report for regularly scheduled office visits and communicate to study personnel about adverse events and concomitant medication.
  • Women of childbearing potential (WOCBP) must use medically approved methods of birth control to avoid pregnancy throughout the study and for up to four weeks after completion of the study in such a manner that the risk of pregnancy is minimized. WOCBP must have a negative serum or urine pregnancy test within 72 hours prior to the start of the study.
  • Male or female, any race or ethic origin

Exclusion Criteria:

  • Patients with current diagnosis of delirium, dementia, amnestic or other cognitive disorder; schizophrenia; borderline or antisocial personality disorder; or any other mental disorder that would interfere with efficacy or safety evaluations or compliance.
  • WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to four weeks after completion of the study. Acceptable methods include oral, injectable or implanted contraceptives, intrauterine devices or barrier methods such as condoms, diaphragm, and spermicides. Women who are pregnant or breast-feeding, or who plan to become pregnant during the study.
  • Patients at significant risk of committing suicide or homicide based on history, mental status exam, or investigator's judgment.
  • Patients receiving psychotherapy (individual, group, marriage, or family therapy) unless participation has been regular for at least 3 months prior to randomization.
  • Patients with clinically significant thyroid pathology that would interfere with efficacy or safety evaluations and patients with a thyroid stimulating hormone (TSH) level > 60% above the upper limit of normal. Patients who are undergoing treatment for their thyroid pathology (e.g. thyroid supplementation) should be stable for at least two months prior to randomization.
  • Patients who have a history or evidence of a medical condition that would expose them to an undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the course of the trial, including but not limited to hepatic, renal respiratory, cardiovascular, endocrine, neurologic, or hematologic disease as determined by the clinical judgment of the investigator.
  • Patients with a history of seizures (except for a single childhood febrile seizure, posttraumatic, alcohol withdrawal) or a history of severe head trauma, or stroke.
  • Patients on medications that may have serious drug-drug interactions with ERC-CBZ
  • Clinically significant abnormal laboratory tests results:

    • Platelets < 75,000/mm³
    • Hemoglobin < 9g/dL
    • Neutrophils, Absolute < 1000/mm³
    • SGOT (AST) >3x Upper limit of Normal
    • SGPT (ALT) > 3x Upper Limit of Normal
    • Creatinine >2mg/dL
    • Diastolic blood pressure >105 mmHg
    • TSH > 60% above Upper Limit of Normal
    • Detectable levels of cocaine and amphetamines in the urine drug screen.
    • Other abnormal laboratory test or vital sign result that in the investigator's judgment, is medically significant, in that it would impact the safety of the patient or the interpretation of the results.
  • Patients who are known to be allergic or hypersensitivity to carbamazepine (or alternative formulations).
  • Patients who have failed an adequate trial of carbamazepine (or alternative formulations) for bipolar depression.
  • Patients who have had recent treatment with a long-acting antipsychotic in which the last dose was less than one full cycle plus one week
  • Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g. infectious disease) illness during the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00203567

Layout table for location information
United States, Alabama
Tuscaloosa Research and Education Advancement Corporation
Tuscaloosa, Alabama, United States, 35404
Sponsors and Collaborators
Tuscaloosa Research & Education Advancement Corporation
Layout table for investigator information
Principal Investigator: Lori L Davis, MD Tuscaloosa Veterans Affairs Medical Center
Layout table for additonal information
Responsible Party: Lori L. Davis, M.D.; Chief, Research Service, Tuscaloosa Research Education & Advancement Corporation Identifier: NCT00203567    
Other Study ID Numbers: TREAC Equetro in Bipolar
TREAC Equetro in Bipolar
First Posted: September 20, 2005    Key Record Dates
Last Update Posted: June 24, 2008
Last Verified: June 2008
Keywords provided by Tuscaloosa Research & Education Advancement Corporation:
bipolar depression
carbamazepine ER
Additional relevant MeSH terms:
Layout table for MeSH terms
Psychotropic Drugs
Depressive Disorder
Bipolar Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders
Bipolar and Related Disorders
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cytochrome P-450 CYP3A Inducers
Cytochrome P-450 Enzyme Inducers